U.S. NASAL SPRAY MARKET ANALYSIS

U.S. Nasal Spray Market, By Product Type (Steroid Sprays, Antihistamine Sprays, Decongestant Sprays, Others), By Type (Prescription and Over-the-Counter), By Indication (Allergic Rhinitis, Nasal Allergies, Nasal Congestion, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

On February 2, 2024, Lupin, a pharmaceutical company, launched Cyanocobalamin Nasal Spray, 500 mcg/spray in U.S. The Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device) is a generic equivalent of Nascobal Nasal Spray, 500 mcg/spray of Par Pharmaceutical, Inc., a pharmaceutical company.
In March 2023, Pfizer, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults
In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, launched RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older

U.S. Nasal Spray Market Report Snapshots